SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-289922
Filing Date
2023-12-06
Accepted
2023-12-06 16:21:30
Documents
12
Period of Report
2023-12-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d98332d8k.htm   iXBRL 8-K 78409
  Complete submission text file 0001193125-23-289922.txt   212561

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nltx-20231206.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nltx-20231206_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nltx-20231206_pre.xml EX-101.PRE 11265
6 EXTRACTED XBRL INSTANCE DOCUMENT d98332d8k_htm.xml XML 3400
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 231469856
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences